New Vaccine Offers Hope for Pancreatic and Colorectal Cancers

Pancreatic and colorectal cancers are notoriously challenging to treat, often leading to high recurrence rates after therapy. However, a new vaccine, ELI-002 2P, shows promise based on encouraging results from a recent clinical trial.

This vaccine, developed by a team of researchers across the United States, targets mutations in the KRAS gene, which accounts for 93% of pancreatic cancer cases and 50% of colorectal cancer cases. It employs a delivery method that directs the vaccine’s active components to the lymph nodes, thereby targeting areas of the immune system harboring various immune cells.

“This is an exciting advance for patients with KRAS-driven cancers, especially pancreatic cancer, where recurrence following standard treatments is almost inevitable and effective options are scarce,” says medical oncologist Zev Wainberg from UCLA.

The study involved 20 individuals recovering from pancreatic cancer and five from colorectal cancer. All had undergone surgery to remove tumors but showed signs that their cancer might return.

After a series of vaccine injections, results were encouraging. An impressive 84% of participants developed mutant-KRAS-specific T cells to combat the mutated gene’s effects, and 24% saw visible traces of tumors erased completely.

Notably, among those who exhibited the strongest immune responses—17 out of 24—most remained cancer-free during a follow-up conducted almost 20 months later. For such aggressive cancers, those results are quite remarkable.

“We found that patients with robust immune responses to the vaccine tended to remain disease-free, living significantly longer than anticipated,” Wainberg adds.

Overall, participants in the study saw a median relapse-free survival of 16.33 months and a median overall survival of 28.94 months—figures that far exceed typical expectations for these types of cancer.

What’s particularly appealing about ELI-002 2P is its classification as an ‘off-the-shelf’ vaccine, suggesting it can be widely distributed without the need for individualized treatments, which can be time-consuming and resource-intensive.

While more trials are necessary to fully assess the vaccine’s risks and benefits, there’s strong evidence suggesting it could prolong lives, especially considering the high recurrence and mortality rates associated with pancreatic and colorectal cancers.

Interestingly, the researchers noted the vaccine might also train the immune system to tackle other cancer mutations, hinting at a broader application in improving future cancer treatments.

“Targeting KRAS has always been a tough nut to crack in cancer therapy,” Wainberg notes. “This study indicates that the ELI-002 2P vaccine can safely and effectively train the immune system to recognize and confront cancer-promoting mutations.”

“It presents a promising strategy for generating precise, lasting immune responses without the complexity or costs associated with fully personalized vaccines.”

The research findings have been published in *Nature Medicine*.